Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Fineline Cube Jan 30, 2026
Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026
Company Legal / IP R&D

Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology

Fineline Cube Sep 12, 2024

Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization

Fineline Cube Sep 12, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...

Company Deals

Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy

Fineline Cube Sep 12, 2024

Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...

Policy / Regulatory

China Aims to Fortify Insurance Industry by 2035 with New State Council Directives

Fineline Cube Sep 12, 2024

The State Council has issued the “Several Opinions on Strengthening Supervision, Preventing Risks, and Promoting...

Company Drug

Suzhou GenAssist Launches First-of-Its-Kind Base Editing Drug Trial for Duchenne Muscular Dystrophy

Fineline Cube Sep 12, 2024

Suzhou GenAssist Therapeutic Co., Ltd, a biopharmaceutical company based in China, has announced the commencement...

Company Medical Device

Siemens Healthineers’ 7T MRI System Terra. X Receives NMPA Marketing Approval

Fineline Cube Sep 12, 2024

Siemens Healthineers AG has secured marketing approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting

Fineline Cube Sep 12, 2024

Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...

Company Deals

CSA Medical Inc. Secures USD 53 Million in Series D Financing to Advance Cryotherapy Treatment

Fineline Cube Sep 11, 2024

CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing...

Company

Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape

Fineline Cube Sep 11, 2024

South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development...

Company Deals

Gilead Sciences Partners with AI Firm Genesis Therapeutics to Develop Novel Small-Molecule Therapies

Fineline Cube Sep 11, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into...

Company Deals

Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies

Fineline Cube Sep 11, 2024

Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage...

Company Deals

Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector

Fineline Cube Sep 11, 2024

Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Shows Promising Results in Phase II Study for ALK+ NSCLC

Fineline Cube Sep 11, 2024

Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...

Company Deals

ImmuneOnco Receives Second Payment from Instil Bio, Highlighting Ongoing Licensing Deal

Fineline Cube Sep 11, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the receipt of a further payment...

Company Drug

Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China

Fineline Cube Sep 11, 2024

Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the...

Company Drug

Innovent Biologics Presents Promising Phase I Data for IBI363 in Advanced NSCLC at WCLC

Fineline Cube Sep 11, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has unveiled Phase...

Company Drug

Betta Pharmaceuticals’ MCLA129 for Advanced Solid Tumors Accepted for Review by China’s NMPA

Fineline Cube Sep 11, 2024

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a pharmaceutical company based in China, has announced that...

Company Drug

Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors

Fineline Cube Sep 11, 2024

Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...

Company Medical Device

Medtronic Secures China Market Approval for Pulsed Electric Field Atrial Fibrillation Treatment Devices

Fineline Cube Sep 11, 2024

Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals...

Company Drug Legal / IP

AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute

Fineline Cube Sep 11, 2024

AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...

Posts pagination

1 … 249 250 251 … 616

Recent updates

  • Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611
  • Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials
  • Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21
  • CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio
  • Sanofi Reports 9.9% Sales Growth to EUR 43.6B, Driven by Dupixent and China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Company Drug

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.